Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund

Refred Pharmaceuticals从Atlas Venture、Omega Funds、Forbion和Longwood Fund获得1亿美元的A轮融资

2021-10-14 21:30:07 BioSpace


Disease-modifying therapeutics for patients with genetic diseases caused by mutations in ABC transporters CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund. Rectify plans to use this financing to fund the company through its first human proof-of-concept (POC) studies. ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system. Rectify is developing a pipeline of PFMs to restore ABC transporter function for patients with serious genetic diseases. “We founded Rectify to deliver life-changing therapies to patients with serious genetic diseases,” said Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture. “I am excited to lead a team of exceptional drug hunters as we build a pipeline of disease-modifying therapeutics across multiple therapeutic areas, with the financing to achieve our first human POC.” Jonathan Moore, Ph.D., Chief Scientific Officer, founded Rectify with Atlas Venture in 2020. Previously, Dr. Moore was a founding scientist at Vertex Pharmaceuticals Incorporated, where he pioneered efforts to treat people with cystic fibrosis by developing precision therapies targeting CFTR, a member of the ABC transporter family. “Outside of CFTR, there are currently no approved therapies that restore ABC transporter function, addressing the underlying cause of disease. Rectify is expanding the application of this proven approach to provide disease-modifying therapies for people living with serious genetic diseases caused by loss-of-function mutations,” said Dr. Moore. “Rectify’s Positive Functional Modulators have the potential to change the lives of patients with diseases caused by mutations in ABC transporters. We are gratified to have had the opportunity to found and seed the company with Jon and to be working with the fantastic people there," said Jason Rhodes, partner at Atlas Venture, previously founding Chief Executive Officer of Rectify and now Executive Chair of Rectify’s Board of Directors. “We are delighted to have co-led this financing alongside this strong group of experienced investors,” said Otello Stampacchia, Ph.D., Founder and Managing Partner, Omega Funds. “The seasoned management team at Rectify leaves us feeling confident in the future growth of this promising company, and we look forward to supporting them on their mission to deliver life-changing therapies for patients with rare genetic diseases.” Leadership team In addition to Dr. Devraj and Dr. Moore, Rectify Pharma’s leadership team includes Tracey Dawson, Ph.D., Chief Operating Officer, Janeta Popovici-Muller, Ph.D., Senior Vice President, Head of Drug Discovery, and Alastair Garfield, Ph.D., Senior Vice President, Head of Biology. Rectify’s Board includes successful biotechnology company builders and its scientific advisors are experienced life science innovators with extensive expertise in drug discovery, structural biology, and liver diseases. Board of Directors Jason Rhodes (Executive Chair), Partner, Atlas Venture Rajesh Devraj, Ph.D., President and Chief Executive Officer, Rectify Pharma Jonathan Moore, Ph.D., Founder and Chief Scientific Officer, Rectify Pharma Jodie Morrison, Venture Partner, Atlas Venture Otello Stampacchia, Ph.D., Founder and Managing Partner, Omega Funds Marco Boorsma, Ph.D., General Partner, Forbion David Steinberg, General Partner, Longwood Fund Scientific Advisory Board Richard Chesworth, DPhil, Independent R&D Consultant Bob Copeland, Ph.D., President, Co-Founder and Chief Scientific Officer, Accent Therapeutics Richard Thompson, BM BCh, DM, Professor of Molecular Hepatology, School of Immunology & Microbial Sciences at King’s College London Jamie Williamson, Ph.D., Professor, Department of Integrative Structural and Computational Biology, Scripps Research Institute About Rectify Pharmaceuticals, Inc. (“Rectify”) Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas. Rectify was founded, seeded, and launched by Atlas Venture and is headquartered in Cambridge, Massachusetts. For more information, please visit About Atlas Venture Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high-impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit About Omega Funds Founded in 2004, Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target our world's most urgent medical needs. Omega focuses on identifying and supporting companies through value inflection points across the full arc of innovation, from company formation through clinical milestones and commercial adoption. Omega Funds' portfolio companies have brought 46 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others. For more information, please visit About Forbion Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 70 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. For more information, please visit: About Longwood Fund Longwood Fund is a leading venture capital firm dedicated to creating and investing in novel healthcare companies that develop important treatments to help patients while targeting significant value for investors. The Longwood team has a long history of successfully launching and building important life science companies while providing operational leadership and strategic guidance. Collectively, the Partners at Longwood Fund have co-founded 23 companies with over 20 launched or marketed drugs and therapies, as well as over two dozen clinical-stage assets, all focused on helping patients in need. Companies founded by Longwood Fund, or its principals prior to the founding of the Firm, as lead investor and CEO/CBO include Vertex, Acceleron, Momenta, Alnylam, Sirtris, Vor, TScan, Pyxis Oncology, Immunitas, Be Biopharma, ImmuneID, and Tome Bio. For more information, please visit View source version on Sarah Sutton/Michael Barron Argot Partners 212-600-1902 Source: Rectify Pharmaceuticals, Inc. View this news release online at:
ABC转运蛋白突变引起的遗传病患者的疾病改良疗法 马萨诸塞州剑桥--(商业网)--Refreate Pharmaceuticals,Inc.(“Refreate”)是一家生物技术公司,开发积极功能调节剂(PFMs),用于恢复ABC转运体功能的疾病调节疗法,今天宣布已完成由Atlas Venture,Omega Funds,Forbion和Longwood Fund共同牵头的1亿美元a系列融资。纠正计划使用这笔资金来资助该公司通过其首次人类概念验证(POC)研究。 ABC转运蛋白是一个由48个成员组成的膜结合蛋白家族,在肺、肝、胃肠道、眼和中枢神经系统等多个器官系统和治疗领域具有病因性功能缺失突变。Refred正在开发一种PFMs管道,以恢复严重遗传病患者的ABC转运蛋白功能。 Atlas venture的总裁兼首席执行官兼风险合伙人拉杰什·德夫拉杰博士说:“我们创建Refrect是为了向严重遗传病患者提供改变生活的治疗。”“我很高兴领导一个由杰出的药物猎人组成的团队,因为我们在多个治疗领域建立了一条疾病治疗管道,并获得了实现我们第一个人类POC的资金。” 首席科学官乔纳森·摩尔博士在2020年与阿特拉斯创投公司创建了整改公司。此前,摩尔博士是顶点制药公司的创始科学家,在那里,他率先通过开发针对CFTR的精准疗法来治疗囊性纤维化患者,CFTR是ABC转运体家族的成员。“在CFTR之外,目前没有批准的治疗方法可以恢复ABC转运蛋白的功能,解决疾病的潜在原因。摩尔博士说:“矫正正在扩大这种被证明的方法的应用,为患有由功能缺失突变引起的严重遗传病的人提供疾病治疗。” “矫正的积极功能调节剂有可能改变由ABC转运蛋白突变引起的疾病患者的生活。阿特拉斯风险投资公司的合伙人杰森·罗兹(Jason Rhodes)说:“我们很高兴有机会与乔恩一起创建和种子公司,并与那里出色的人合作。”杰森·罗兹曾是整改公司的创始首席执行官,现在是整改公司董事会的执行主席。 Omega Funds创始人兼管理合伙人Otello Stampacchia博士说:“我们很高兴能与这群经验丰富的投资者一起共同领导这笔融资。”“矫正公司经验丰富的管理团队让我们对这家充满希望的公司的未来增长充满信心,我们期待着支持他们为罕见遗传病患者提供改变生活的治疗的使命。” 领导团队 除了Devraj博士和Moore博士之外,Refree Pharma的领导团队还包括首席运营官Tracey Dawson博士、高级副总裁兼药物发现负责人Janeta Popovici-Muller博士和高级副总裁兼生物学负责人Alastair Garfield博士。 Reprect的董事会包括成功的生物技术公司建设者,其科学顾问是经验丰富的生命科学创新者,在药物发现、结构生物学和肝脏疾病方面拥有广泛的专业知识。 董事会 Jason Rhodes(执行主席),Atlas Venture合伙人 Rajesh Devraj,博士,Refect Pharma总裁兼首席执行官 乔纳森·摩尔博士,整改制药公司创始人兼首席科学官 朱迪·莫里森,Atlas Venture风险投资合伙人 Otello Stampacchia,博士,Omega Funds创始人兼管理合伙人 Marco Boorsma博士,Forbion普通合伙人 大卫·斯坦伯格,朗伍德基金普通合伙人 科学咨询委员会 理查德·切斯沃思,DPhil,独立研发顾问 鲍勃·科普兰博士,口音治疗公司总裁、联合创始人兼首席科学官 Richard Thompson,BM BCh,DM,伦敦国王学院免疫学与微生物科学学院分子肝病学教授 杰米·威廉姆森,博士,教授,斯克里普斯研究所综合结构与计算生物学系 关于Refred Pharmaceuticals公司(“Refred”) Refrect正在开发治疗疾病的精确疗法,恢复ABC转运蛋白的功能,以解决严重遗传疾病的潜在原因。该公司的管道横跨多个治疗领域。Refect是由Atlas Venture创建、种子和发起的,总部设在马萨诸塞州剑桥。 欲了解更多信息,请访问。 关于Atlas Venture 阿特拉斯风险投资公司是一家领先的生物技术风险投资公司。从1993年起,我们一直致力于建立突破性的生物技术初创公司,目标是通过做好事来做好事。我们与杰出的科学家和企业家并肩工作,将高影响力的科学转化为病人的药物。我们以种子为主导的风险创建战略严格选择和集中投资于最引人注目的机会,以建立可扩展的业务和实现价值。 欲了解更多信息,请访问。 关于欧米茄基金 欧米茄基金成立于2004年,是一家领先的国际投资公司,创建和投资生命科学公司,目标是我们世界上最紧迫的医疗需求。欧米茄专注于通过整个创新领域的价值拐点来识别和支持公司,从公司成立到临床里程碑和商业应用。欧米茄基金的投资组合公司在多个治疗领域为市场带来了46种产品,包括肿瘤学、罕见疾病、精准医学和其他。 欲了解更多信息,请访问。 关于Forbion Forbion是一家专注于生命科学的风险投资公司,在荷兰、德国和新加坡设有办事处。Forbion投资于活跃在(生物)制药领域的生命科学公司。Forbion管理超过17亿欧元的多个基金战略,涵盖(生物)制药药物开发的所有阶段。福比恩目前的团队由20名生命科学投资专业人士组成,自90年代末以来,他们在70多家公司取得了成功投资,创造了令人印象深刻的业绩记录。该公司是《联合国负责任投资原则》的签署国。除了财务目标外,Forbion还选择对病人的健康和福祉有积极影响的投资。其投资者包括EIF(通过其欧洲复苏方案)、LfA、Dutch Venture Initiative(DVI)、AMUF和EFSI设施以及KfW Capital(通过“ERP-风险资本基金投资”方案)。Forbion与BGV经营一家合资企业,BGV是种子基金和早期基金的经理,尤其专注于比荷卢和德国。 欲了解更多信息,请访问 关于朗伍德基金 朗伍德基金是一家领先的风险投资公司,致力于创建和投资新的医疗保健公司,这些公司开发重要的治疗方法来帮助患者,同时为投资者提供重要的价值。Longwood团队在提供运营领导和战略指导的同时,拥有成功创办和建设重要生命科学公司的悠久历史。朗伍德基金的合作伙伴共同创建了23家公司,拥有20多种已上市或上市的药物和疗法,以及20多种临床阶段资产,都专注于帮助有需要的患者。由朗伍德基金或其在公司成立前的负责人作为首席投资者和首席执行官/CBO创建的公司包括Vertex、Acceleron、Momenta、Alnylam、Sirtris、Vor、TScan、Pyxis Oncology、Immunitas、Be Biopharma、ImmuneID和Tome Bio。 欲了解更多信息,请访问。 在businesswire.com查看源代码版本: 莎拉·萨顿/迈克尔·巴伦 隐语伙伴 212-600-1902 资料来源:Refect制药公司。 在网上查看此新闻稿: